D&D Pharmatech Receives Fast Track Designation from FDA for DD01 – Novel Treatment for NASH/MASH
D&D Pharmatech, a biotech company, has been granted Fast Track designation by the US Food and Drug Administration (FDA)...
Jon Napitupulu
EMA Accepts Rocket Pharma’s RP-L102 Application for Fanconi Anemia Treatment
Rocket Pharmaceuticals, a late-stage biotechnology company, has announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization...
US FDA Accepts Astrazeneca License Application for Datopotamab Deruxtecan in Metastatic HR+, HER2- Breast Cancer
Biopharmaceutical companies AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted in the US,...
VBI Vaccines Boosts Strategic Partnership to Propel MRNA-Launched EVLP Vaccine Platform
Biopharmaceutical firm VBI Vaccines has expanded its collaboration with the Canadian government, with the latter contributing the remaining CAD$28...
QLS-111 by Qlaris Bio Enters Phase II Trials for IOP Reduction
Qlaris Bio, Inc., a biotechnology firm focusing on ophthalmic diseases, has announced the initiation of two Phase II clinical...
Mirum’s Livmarli Gets Positive CADTH Reimbursement Nod for Alagille Syndrome in Canada
The Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive...
MRD Testing Market Analysis 2024: Revolution in Cancer Management Drives Growth
The MRD (Minimal Residual Disease) testing market is experiencing substantial growth, with its value projected to increase from $1.67...
Zai Lab’s Partner BMS Confirms KRYSAL-12 Trial Success for Krazati in KRASG12C-Mutated Cancer
Zai Lab Limited, in collaboration with Bristol Myers Squibb, announced significant progress in the fight against lung cancer with...
Pyros Pharmaceuticals Launches Vigpoder™ (Vigabatrin) for Market
Pyros Pharmaceuticals, Inc., a leading company in the development of specialty pharmaceuticals for rare diseases, has announced the availability...
BMS Updates on Phase 3 Yellowstone Trial for Zeposia in Crohn’s Disease
Bristol Myers Squibb (BMY) has reported that a Phase 3 study within the YELLOWSTONE clinical trial program, which was...